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C
ellular suicide, or apoptosis, has 
its up side. It keeps cancer in 
check and helps prune extra cells 
during development. But at the wrong 
time or place, apoptosis can have 
devastating consequences, as seen in 
stroke victims and patients suffering from 
Alzheimer’s and Huntington’s diseases.
Among the fi  rst scientists who dissect-
ed the cellular mechanism of apoptosis 
was Junying Yuan, who 
cloned the fi  rst  two 
genes needed for cell 
death in worms, ced-3 
(1) and ced-4 (2). She 
found that ced-3 and its 
mammalian counter-
part encode the cell’s 
executioner—a cyste-
ine protease (3) that is 
now known as the pro-
totypical caspase.
Recently, Yuan re-
ceived a Pioneer Award that unveiled her 
lab’s new interest in the removal of misfold-
ed proteins from a cell. We caught up with 
Yuan to discuss her interests, including how 
this new path intersects with cell death.
A REVOLUTIONARY EDUCATION
How did you get your start in science?
Both of my parents and others in my fam-
ily were involved in science—they were 
doctors and engineers. But that career op-
tion was not a possibility for me when I 
was growing up in China. That was during 
the Cultural Revolution, so essentially all 
the universities were closed. I was consid-
ering whether I wanted to be a farmer or a 
factory worker; those were the options.
But I was a good student, and I had a 
high school teacher, Mr. Lu, who believed 
that I should go to college somehow. 
Normally, someone from a family like 
mine—intellectuals—would have been 
sent to a remote farm to work, but he 
helped me stay in Shanghai, where I 
worked in a factory on heavy machines.
Fortunately, at that time, the Cultural 
Revolution was ending, and China reinsti-
tuted college entry exams. Mr. Lu asked 
me to study the old high school curriculum, 
from before the Cultural Revolution, 
because my education had been really 
basic and elementary. You know, every 
semester English started with, “Long live 
Chairman Mao” [laughs].
So I studied for four months really, 
really hard. They estimated that probably 
more than 100,000 people took the exam, 
and I actually scored the highest. And I 
went to Fudan University in Shanghai.
When I needed to decide what to study, 
my grandfather, who was a professor of 
organic chemistry, told me, “Study biology, 
it’s good for girls. And chemistry is also 
very interesting.” He said the combination 
of chemistry and biology, meaning bio-
chemistry, would be the thing of the future.
What made you decide to leave for the 
States?
That was also a coincidence, because 
when I was in college, it wasn’t really 
possible to leave the 
country to study. But 
my mother was a 
professor at a medi-
cal school, and she 
told me that she 
heard rumors that 
the best student in 
her college would be 
sent abroad to study. So I applied to grad-
uate school in her medical college, and I 
again scored best on the entrance exam.
That qualifi  ed me to take another na-
tional test sponsored by Harvard. They 
had organized a program to bring Chinese 
students to top graduate schools in America. 
That’s how I got to Harvard.
MORBID INTERESTS
How did you get interested in cell 
death?
One of the courses I took at Harvard was 
called Neurological Diseases, and they 
actually brought in patients who had dis-
eases like Alzheimer’s and Huntington’s. 
That left a really deep impression on me. 
Even today, I can remember exactly what 
that Huntington’s patient looked like.
I also took a class on developmental 
neurobiology. At the time, classical work 
done by Ron Oppenheim and others had 
shown that up to 50% of neurons die dur-
ing development. I was intrigued that cell 
death, something associated with disease, 
was also associated with a beautiful thing 
like development.
At the end of the courses, I concluded 
two things. The fi  rst was that all of these 
neurodegenerative diseases are caused by 
the selective death of specifi  c populations 
of neurons that should not have died. I 
thought it was striking that early in em-
bryonic development you can have very 
orderly, selective neuronal death. And 
later on in life, you can also have very 
selective neuronal deaths. It was a fi  rst-year 
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Aggregates (left) of mutant proteins (green) 
with polyQ expansions kill neurons. Preventing 
aggregation (right) saves neurons and might 
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student’s fantasy, but I thought, “There 
may be some similarities between them.”
I even talked to some professors about it. 
But their response was always negative, 
because nobody believed that cell death was 
something interesting or regulated. They 
just thought neurons died in Alzheimer’s 
because they were poisoned, and neurons 
died in development because they were 
starved to death by a lack of growth factors.
The second thing I concluded was that, 
although we were hearing lectures from 
eminent physicians, they really didn’t 
know anything about these diseases in 
terms of mechanism. All they could tell the 
patient was which way they were going to 
die. And if I were the patient, I really 
wouldn’t care which way it was; they were 
all pretty bad. That made me interested in 
cell death as a biological mechanism.
You got your Ph.D. from Harvard even 
though you worked in an MIT lab. 
How did that come about?
Nobody at Harvard then was studying cell 
death. So I went to our graduate director, 
Ed Kravitz, and said, “I cannot fi  nd a lab 
that I want to work in here.” Thinking back, 
anybody else would probably have thought 
I was so arrogant—I’d just recently arrived 
from China, and I defi  nitely didn’t speak 
English well. “What 
do you mean? None of 
the hundreds of labs 
here would be good 
enough for you?” For-
tunately, Ed was really 
nice to students, and 
he said, “Oh, if you 
can’t fi  nd a lab here, 
you can work in Cam-
bridge,” meaning on the Harvard main 
campus because I was at the medical 
school, “or you can even go to MIT.”
That made me really happy because I 
had just heard Bob Horwitz from MIT talk 
about cell death in C. elegans. He believed 
that there were cells that were determined 
to die, just like there are cells determined to 
be a neuron. It was striking to me that his 
ced-3 and ced-4 mutants had such specifi  c 
defects in cell death, and nothing else 
seemed to be wrong with them. I thought 
those were the most interesting mutants I’d 
ever heard of. So I ended up in Bob Hor-
witz’s lab, but with a degree from Harvard.
ENTERING A NEW FOLD
That’s where you started your famous 
work on caspases and cell death. But you 
were recently given a Pioneer Award to 
study the removal of misfolded proteins. 
What’s the connection?
From all this work, I’ve realized that 
even though apoptosis and caspases are 
contributing to many neurodegenerative 
diseases—Aβ can induce apoptosis in 
Alzheimer’s, PolyQ can induce apoptosis 
in Huntington’s—for 
most of these diseases, 
inhibiting cell death 
will be too late for the 
patient. The disease ac-
tually starts with neuro-
nal dysfunction caused 
by these proteins. In 
many cases, the mutant 
proteins manifest as an 
accumulation of misfolded proteins. So I 
think it’s very important to learn how cells 
normally remove misfolded proteins.
Maybe the best example is Hunting-
ton’s disease. The penetrance is 100% 
when they have PolyQ repeats longer than 
40-something. The key, though, is why 
does this person live fi  ne for 40 or 50 years, 
and then all of a sudden have Huntington’s 
disease? It’s not because these patients 
don’t express PolyQ proteins when they’re 
young. It’s pretty much always around.
So we’re hoping to understand what 
tips the threshold. Because if we can push 
that back another 10 or 20 years, it will 
mean a cure for many of these people.
What are you learning about misfolding 
and disease now?
I don’t want to give away too much of 
our progress yet. But the key I think is 
accumulation. And what leads to accumu-
lation must be the degradation mecha-
nism—it’s somehow defective.
Do you think the Pioneer Awards are a 
promising avenue for medical research?
I think they are very good. What it does 
most for me is really free me from writing 
grants all the time instead of doing more 
productive work. I can follow the work in 
the lab better, I can really think more in 
depth about the projects. It gives me more 
time with my students and postdocs.
The Pioneer people are looking for 
someone to do things that are different 
from what they originally studied, but the 
hope is to spark creativities in the differ-
ences. The other thing they look for is a 
good track record of creativity, a willing-
ness to stick your neck out and do some-
thing different. That pushed me toward 
working on a subject that I honestly 
wouldn’t have worked on otherwise.
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Disease-associated neuronal death can happen by apoptosis (left) or via an unusual pathway 















“For most of 
these diseases, 
inhibiting cell death 
will be too late for 
the patient.”